We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

27 hedge funds and large institutions have $12M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% less capital invested

Capital invested by funds: $14.1M → $12M (-$2.12M)

16% less funds holding

Funds holding: 3227 (-5)

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
27
Holders Change
-5
Holders Change %
-15.63%
% of All Funds
0.6%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
4
Reduced
11
Closed
4
Calls
$93K
Puts
Net Calls
+$93K
Net Calls Change
-$85K
Name Holding Trade Value Shares
Change
Change in
Stake
PCM
26
Princeton Capital Management
New Jersey
$1K
Walleye Trading
27
Walleye Trading
New York
-$222K -515 Closed
ARTA
28
A.R.T. Advisors
New York
-$42K -99 Closed
VF
29
Virtu Financial
New York
-$41K -96 Closed
TRCT
30
Tower Research Capital (TRC)
New York
-$1K -2 Closed

FRTX Hedge Fund Activity: Q4 2018 in Review

27 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2018, worth a combined $12M — down 15% from $14.1M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of FRTX and 0 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 4 added.

The largest buyer was Sio Capital Management, adding an estimated $468K. The largest seller was Walleye Trading, exiting entirely with an estimated $222K sold.

  • 27 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2018, down from 32 in Q3 2018.
  • Funds reported $12M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2018, down 15% quarter-over-quarter.
  • 0 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2018 and 4 closed out, a net change of -4 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2018 was Sio Capital Management, an estimated $468K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2018 was Walleye Trading, an estimated $222K sold.

Based on aggregated 13F filings for Q4 2018.